Researchers have reported that the telomerase reverse transcriptase gene promoter was altered in 69 percent of 54 cases of bladder cancer. Telomerase reverse transcriptase alterations frequently co-occur with alterations in recently identified bladder cancer genes such as STAG2 and KDM6A.